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R0Vaccination is the main tool for controlling infectious diseases in livestock. Yet current vaccines only pro-
vide partial protection raising concerns about vaccine effectiveness in the field.
Two successive transmission trials were performed involving 52 pigs to evaluate the effectiveness of a
Porcine Reproductive and Respiratory Syndrome (PRRS) vaccinal strain candidate against horizontal
transmission of a virulent heterologous strain. PRRS virus, above the specified limit of detection, was
observed in serum and nasal secretions for all but one pig (the exception only tested positive for serum),
indicating that vaccination did not protect pigs from becoming infected and shedding the heterologous
strain. However, vaccination delayed the onset of viraemia, reduced the duration of shedding and signif-
icantly decreased viral load throughout infection. Serum antibody profiles indicated that 4 out of 13 (31%)
vaccinates in one trial had no serological response (NSR).
A Bayesian epidemiological model was fitted to the data to assess the impact of vaccination and pres-
ence of NSRs on PRRS virus transmission dynamics. Despite little evidence for reduction in the transmis-
sion rate, vaccinated animals were on average slower to become infectious, experienced a shorter
infectious period and recovered faster. The overall PRRSV transmission potential, represented by the
reproductive ratio R0 was lower for the vaccinated animals, although there was substantial overlap in
the credibility intervals for both groups. Model selection suggests that transmission parameters of vacci-
nated pigs with NSR were more similar to those of unvaccinated animals. The presence of NSRs in a pop-
ulation, however, seemed to only marginally affect the transmission dynamics.
The results suggest that even when vaccination can’t prevent infection, it can still have beneficial
impacts on the transmission dynamics and contribute to reducing a herd’s R0. However, biosecurity
and other measures need to be considered to decrease contact rates and lower R0 below 1.
 2020 Elsevier Ltd. All rights reserved.1. Introduction
For decades, vaccination has constituted one of the main tools
for preventing and controlling infectious disease in livestock. The
major aims of veterinary vaccines are to improve the health of ani-
mals and prevent or reduce pathogen transmission, therebyincreasing production of livestock in a cost-effective manner [1].
However, the potential of a vaccine to control an infectious disease
in livestock is controversial as many vaccines are leaky [2] and may
not protect all vaccinated animals from disease which may com-
promise vaccine effectiveness in the field [3]. This is pertinent for
Porcine Reproductive and Respiratory Syndrome (PRRS) which,
despite wide-spread vaccination, remains one of the most costly
diseases afflicting the global swine industry [4], directly in terms
of the economic loss on affected farms and indirectly due to bacte-
rial complications that require the use of antibiotics [5]. The annual
losses due to PRRS have been estimated at $2.5 Billion in the US
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issues, including late abortions, early farrowings and stillbirths, as
well as respiratory disease, fever, and poor growth in pigs of all
ages.
PRRS virus (PRRSV), the causative agent of PRRS, is a small,
enveloped, positive-strand RNA virus in the Arteriviridae family, a
family known for large genetic and antigenic variability within
each species of virus [7]. The source of genetic variation is the
virus’ ability to rapidly mutate and create new variants [7]. As a
result, the clinical pathology can vary substantially between PRRSV
isolates [8]. Although PRRSV is not considered zoonotic [9], out-
breaks in pigs are associated with increased susceptibility to sec-
ondary bacterial [10] and viral [11] infections. PRRSV was first
isolated in the late 1980s and was divided into the genotypes
PRRSV-1 (European origin) and PRRSV-2 (North American origin),
based on genetic, antigenic and pathogenic differences [12]. PRRSV
has a high mutation rate and, over time, the genetic diversity of the
virus has increased [13,14]. Fast evolution and high genetic diver-
sity severely compromise the ability of both natural and vaccine-
induced immunity to provide full protection from infection and
disease.
Although the first PRRS vaccine has been commercially avail-
able and widely used for over two decades, the prevalence of
PRSSV infection in herds remains high as no fully effective vaccine
(i.e. that totally prevents disease and virus spread) has been devel-
oped [15,16]. Failure of commercial vaccines to confer sterilizing
immunity against many PRRSV field strains may promote mutation
of PRRSV to adapt to new immune environments of the host ani-
mals [17,18].
All current PRRS vaccines are leaky [19]. There is also increasing
awareness of substantial heterogeneity in vaccine response
[20,21]. In a theoretical modelling study, Bitsouni et al. [3] demon-
strated that even leaky vaccines can substantially reduce the risk of
disease invasion and spread in a herd, if the vaccine reduces host
infectivity or the duration of the infectious period. However, their
model also predicts that the presence of vaccinated pigs with no
serological response compromises effective vaccine coverage in a
herd and can substantially increase the transmission potential of
the infection (R0).
As PRRSV continues to spread rapidly all over the world, with
more virulent strains emerging [22,23], concerns regarding the
evaluation of vaccine effectiveness in the field start to increase.
Whilst vaccine trials routinely assess protective efficacy of vaccines
and their effects on diverse immunological, virological and patho-
logical parameters, less is known about how PRRS vaccines affect
the transmission dynamics of PRRS within a herd [4,24].
The aim of this study was to evaluate the impact of attenuated
PRRS-strain vaccination on heterologous strain transmission,
including the effect of vaccinated pigs with no serological response
(NSR), on transmission dynamics using a vaccination-contact ani-
mal experiment. This trial mimics the natural horizontal transmis-
sion in field conditions.
2. Methods
2.1. Animals and housing
Two successive transmission trials were performed (Fig. 1a&b)
at the Faculty of Veterinary Medicine at Ghent University. Fifty-
two 3 to 5-week-old conventional pigs (twenty-six for each inde-
pendent experiment) were obtained from a PRRSV negative farm.
No other relevant pathogens (SIV, PCV2) were detected in the ani-
mals. The pigs were randomly allocated into two groups (vacci-
nated, unvaccinated), based on body weight. All pigs were
housed in separated stables in a biosafety level 2 (BSL2) facility
and their health status was monitored closely on a daily basis.The study was conducted in compliance with the provisions of
KB 29/05/2013 (Belgian implementation of the European Directive
2010/63/EU). The study was evaluated by the local Ethical Com-
mittee of the Faculty of Veterinary Medicine and Bioscience Engi-
neering and approved with number 2017/110 (Annex 7).
2.2. Vaccination and challenge viruses
The Modified Live Virus (MLV) Flanders08att was attenuated by
serial passaging on MARC-145 as described previously [25]. The
attenuated strain was thawed and diluted in PBS (pH 7.4) to a con-
centration of 105 TCID50 per dose. Vaccination was done by intra-
muscular (IM) injection in the neck with a single 2 ml dose
[26,27]. Challenge was performed with 105 TCID50 of the PRRSV
strain Flanders13, a highly virulent strain (see Supplementary
Appendix A) with 84% sequence similarity with Flanders08att.
2.3. Inoculation experimental design
On 34 days post vaccination (dpv), three pigs (shedders) from
each group were transferred to another unit and inoculated with
PRRS virus (PRRSV strain Flanders13) intranasally, 1 ml of inocu-
lum per nostril (Fig. 1a). In the vaccinated group the method of
selection varied between experiments. In Trial 1, 4 out of 13 pigs
(31%) in the vaccination group had no serological response (NSR)
on 28 dpv (Fig. 1b; Supplementary Appendix A). One NSR pig and
2 pigs with serological response were randomly selected for direct
inoculation (shedders). This was done as it was thought to mimic
the natural proportions of pigs with and without serological
response. All vaccinated pigs had a serological response in Trial 2
so the selection of pigs was done at random in both groups.
The intranasally inoculated shedders were re-introduced (35
dpv / 0 days post contact (dpc)) to their original units comprising
10 PRRSV-negative pen mates (contact pigs). After reintroduction,
sampling (blood and nasal secretions) was done every three days
until 30 dpc and lastly on day 35 dpc. At 35 dpc, the pigs were
humanely euthanized by intravenous injection of pentobarbital.
During sampling, effort was made to reduce transmission between
contact groups. Any piglet bleeding after sampling was isolated
until the bleeding stopped. In between sampling of pigs, gloves
were removed and replaced with new ones in order to prevent
cross-contamination between pigs.
2.4. Sampling: Nasal secretions & blood
Sampling of nasal secretions was done using dry cotton swabs
(one swab per nostril). Nasal swabs were placed into 1 ml of virus
transport medium [26,27], vortexed, collected and stored at 70 C
for subsequent virus determination. Sampling of nasal secretions
was done every three days from 35 dpv (0 dpc) up to 27 dpc
(Fig. 1b).
Blood samples (3–10 ml) were collected from the pigs by the
vena cava cranialis puncture method as described previously [26].
After collection, the blood was centrifuged at 3000 rpm for
10 min at 4 C, collected and stored at –70 C for either virus or
antibody determination. Blood samples for antibody titre measure-
ments were collected at arrival (7 dpv), vaccination (0 dpv) and
every 7 days up to 35 dpv (Fig. 1b; Supplementary Appendix A).
Blood sampling for virus determination was done every three days
until 30 dpc and lastly at 35 dpc (euthanasia) (Supplementary
Appendix A).
2.5. Antibody and viral titre determination
Antibody titres for serum samples were determined using the
immunoperoxidase monolayer assay (IPMA) (Supplementary
(a)
(b)
Fig. 1. Transmission experiment. (a). Timeline of the experiment. This represents 1 replicate of the experimental design comprising 13 pigs (3 shedder pigs and 10 contact
pigs). Numbers represent periods of time: 1 Pre-vaccination; 2 post vaccination; and 3 post contact. Letters represent events: A arrival; B vaccination; C removal of shedders
(n = 3) for inoculation with virus; D infected shedder pigs placed back in contact with pen mates (contact pigs, n = 10); E beginning of post-contact sampling period; F
termination of the experiment. Arrows show when blood (red) and nasal swabs (green) samples were taken, respectively. dpv, days post vaccination. dpc, days post contact.
Note that the diagram represents the complete number of samples. For certain replicates/trials not all samples were collected (see text). (b). Experimental design. Two
consecutive replicates of a transmission experiment (Trial 1 and Trial 2) were performed involving altogether 52 pigs of similar age and weight. Each trial comprised two
contact groups, one consisting of vaccinated (Flanders08att strain) pigs only, and the other one consisting of unvaccinated pigs. In each contact group, 3 pigs were designated
as shedders, and inoculated with PRRSV strain Flanders13 according to the schedule in Fig. 1a, before put back into contact with their corresponding pen mates (n = 10). The
experimental design was the same across the trials with the exception of the presence of pigs that had no serological response (NSR) after vaccination Trial 1 (striped pattern).
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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serum and nasal samples collected post contact (Supplementary
Appendix A). The limit of detection (LOD) was 0.8 logTCID50 per
ml (serum) for viraemia and 2.5 logTCID50 per g (nasal secretion)
for nasal shedding.2.6. Data management and statistical analysis
PRRS viral titre (expressed as TCID50 per ml (serum) or per g
(nasal secretion)) was log-transformed for subsequent analysis.
Pigs were classified as vaccinated, unvaccinated or vaccinated with
no serological response (NSR) for the purposes of analysis. NSRs
were identified by antibody profiles. As there were only 4 NSR pigs
(Trial 1: 1 shedder pig and 3 contact pigs) no formal statistical
comparison was performed using these individuals as the power
was considered too low, however, they are included in all figures
and tables for comparison with vaccinated and unvaccinated pigs.
Differences between vaccinated and unvaccinated pigs were
assessed by examining the viral shedding patterns and viral load.
Analysis of viral shedding profiles was performed using a Gener-
alised Linear Mixed Model (GLMM) (Proc Glimmix, SAS v 9.4).
For a quantitative analysis of viral load, the area under the viralcurve (AUC) for nasal and serum samples of all shedder and contact
pigs was generated using the trapezoidal rule. Values below the
limit of detection (LOD) were treated as LOD/2. Differences
between trial and vaccination status were analysed using a General
Linear Model (GLM) (Proc GLM, SAS version 9.4). All statistical
analyses were performed using SAS version 9.4 (SAS Institute, Cary,
NC) with p < 0.05 as the level of significance.2.7. Estimating the impact of vaccination on PRRSV transmission
dynamics
To assess the impact of vaccination with Flanders08att on trans-
mission of the heterologous PRRSV (Flanders13) strain, a compart-
mental epidemiological model was fit to data from each contact
group in the transmission experiment. Individuals were considered
to be in one of 5 states: susceptible to infection (S), exposed i.e.
infected but not yet infectious (E), infectious (I), latent i.e. infected
but no longer infectious (L), or ‘‘recovered” (R) (Fig. 2a). Transitions
between states (as indicated by the arrows) were assumed to be
Markovian (i.e. they occur with a certain probability per unit time,
irrespective of the history of the individual). Note, R doesn’t repre-
sent a permanently recovered state, as the model allows for transi-
Fig. 2. a. The compartmental epidemiological model. Individuals in the corre-
sponding compartments are susceptible (not yet infected) S, exposed (infected but
not yet infectious) E, infectious I, latent (infected but not infectious) L, and
recovered R (which here means not detectable by the two qPCR tests), respectively.
The parameters bV, kV, pV, cV, jV and dV are transition rate parameters, where V
denotes the fact that these parameters depend on the vaccination status of
individuals. Note, bV is multiplied by ‘‘I”, which is the time-dependent total number
of infected individuals in the same contact group. b. The observation model. This
model identifies possible infection states (S, E, I, L, or R) in the compartmental
epidemiological model at each sampling time based on the individual’s corre-
sponding binary diagnostic test results (negative/positive) for nasal test (here a
positive result is consistent with an individual in the I classification) and a viremia
test (here a positive result is consistent with E, I and L). Considering a possible
realisation for the transition events n, the observation model takes the value p(y|
n) = 1 if putative compartmental state (as determined by n) can be assigned to each
individual at the time when each of the diagnostic test measurements are made,
otherwise p(y|n) = 0. The observations model, therefore, restrict MCMC to only
those states n consistent with the data y.
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state. The disease status of individuals at the beginning of each trial
was assumed known, with shedder pigs in the E state and contact
pigs in the S state.
The identification of states and transition routes in this epi-
demiological model was based on the experimental data (Fig. 3).
For example, the necessity of including the exposed state E was
determined by the serum and nasal swab viral measurements of
the shedder pigs, which were less than the LOD for the first few
days post infection (Fig. 3). The reason for the ‘‘L” state is because
the data shows that serum viraemia levels can persist at a detect-
able level for significantly longer than the nasal swab measure-
ments (Fig. 3). The reverse transitions in Fig. 2a are incorporated
to account for the observed rebound [28,29] in virus above LOD
of a number of pigs (n = 20/52 38.5%) (Fig. 3).
Model fitting was carried out using a Bayesian approach which
generated posterior samples for the model parameters h = {bV, kV,
pV, cV, jV, dV} (where V takes the values ‘‘Vac” for vaccinated,
‘‘Unvac” for unvaccinated and ‘‘NSR” for no serological response)
and unknown transition events n (where each event e represents
a transition that an individual undergoes, e.g. S ? E, with corre-
sponding event time te) (Fig. 2a). Note, the total collection of all
events on all individuals n represents a realisation of the theoreti-
cally possible event sequences occurring in the trials. Although n is
unknown it can be sampled from the posterior, so generating a col-
lection of probable event sequences consistent with the data.
Data y used for model fitting comprised both the nasal swab
and the viraemia test results of each individual (specifically, binary
+ve/ve diagnostic test results were generated with the cut-off
being set by the detection limit of the tests). These binary
measures were used to assign individuals into the appropriate epi-demiological model compartments (S, E, I, L or R) at the observa-
tion times, as specified in Fig. 2b. Application of Bayes’ theorem
to this data implies that the posterior is given by
pðh; njyÞ / p yjnð ÞLðnjhÞpðhÞ; ð1Þ
where the observation model p(y|n) takes the values one or zero
depending on whether n is consistent with y or not, and the latent
process likelihood is given by [30,31].
LðnjhÞ ¼
YZ
z¼1
YEz
e¼1ree
Keðtete1Þ
h i
; ð2Þ
where z goes over all contact groups (Z = 4) and e goes over events
within each contact group (up to total of Ez events). The quantity re
takes the value of the transition rate corresponding to event e (i.e.
transition E ? I of an unvaccinated individual would lead to re =-
kUnvac) and Ke gives the sum of the transition rates for all possible
transitions on all individuals in contact group z immediately prior
to time te. The prior p(h) in Eq. (1) consists of largely uninformative
uniform distributions between 0 and 1 for each of the model param-
eters. Further details about the general approach used above are
given in section 5.3 of [32].
Bayesian inference was performed using Markov chain Monte
Carlo (MCMC) with a large number of iterations to ensure accurate
estimates were generated (with effective sample size exceeding
8000 for each parameter after an initial 20% burn-in period) from
four randomly initialised chains (used to confirm global conver-
gence of parameters). Details of this procedure along with MCMC
diagnostics are given in Supplementary Appendix B.
Because of relatively few NSRs in this study (only 4) it was not
possible to accurately estimate transmission parameters for this
particular class of individuals. Therefore, the following parameter-
isation was implemented:
bNSR ¼ abUnvac þ ð1 aÞbVac; ð3Þ
with corresponding expressions for each of the other parameters in
h. Here a is a new model selection parameter (with flat prior
between 0 and 1) used to choose between two hypotheses: when
a = 0 NSRs behave like vaccinated individuals and when a = 1 they
behave like unvaccinated individuals. Thus, a can be used to per-
form model selection between these two hypotheses. Inference
was performed assuming a flat prior for a between 0 and 1.
R0 estimates were calculated for the vaccinated and unvacci-
nated groups using the following formula
R0;V ¼ bV ðN  1ÞpV ; ð4Þ
where N = 13 is the number of individuals in each contact group and
the subscript V is either ‘‘Vac” or ‘‘Unvac” (note, this expression
ignores the potential rebound of individuals from L to I, which are
later shown to be relatively infrequent, and so actually represents
a lower bound for the true R0). Samples for R0 derived from poste-
rior samples for h were used to generate the plots (here NSRs were
assumed to behave the same as unvaccinated individuals, i.e. a = 1).3. Results
3.1. Antibody response
All vaccinated pigs (n = 26) over the 2 trials developed antibod-
ies except 4 pigs in Trial 1 (1 shedder pig and 3 contact pigs), which
were consequently denoted as having ‘No Serological Response’
(NSR). There were no NSRs in Trial 2. (Supplementary Appendix
A Fig. A1)
Fig. 3. Individual infection diagnostics. Schematic diagram summarising the individual pig results from Trial 1 and Trial 2. The colour of the boxes for each sampling time
(dpc, days post contact) represents whether the virus titre level was above (GT) or below (LT) the limit of detection (LOD). White, viral titre LT LOD; Blue box, vaccinated
pig GTLOD; red box, unvaccinated pig GTLOD; striped box, no serological response to vaccination (NSR) GTLOD; Grey box, no sample taken at this time point. LOD was 2.5 Log
TICD50.g-1 and 0.8 Log TICD50.ml-1 for nasal secretions and serum respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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PRRS virus greater than (GT) the LOD was detected in all contact
pigs (Fig. 3) except for the nasal samples of one piglet (which had
one serum sample GTLOD, suggesting it was also infected). The
proportion of sampling points with virus GTLOD was highest for
the serum samples of contact pigs in the unvaccinated contact
group. By 9 dpc all contact pigs in the unvaccinated contact group
were infected, i.e. had virus GTLOD (85% by 6 dpc) whereas most
contact pigs in the vaccinated contact group were not infected
until 21 dpc (only 18% by 9 dpc). The pattern was similar for the
onset of nasal shedding although the proportion of pigs GTLODwas lower for contact pigs in both the vaccinated and unvaccinated
contact groups when compared to viraemia.3.3. Infection profiles
The proportion of animals GTLOD over the course of the study is
summarised for nasal shedding (Fig. 4a) and viraemia (Fig. 4b) with
95% confidence intervals obtained from GLMM. Contact pigs in the
unvaccinated groupwere infected (Fig. 4b) earlier and shed (Fig. 4a)
virus earlier and longer than contact pigs in the vaccinated group.
The infection profile of NSRs was more similar to contact pigs in
the unvaccinated contact group but this could not be tested statis-
Fig. 4. Virus titre profiles for Nasal shedding (a) and Viraemia (b). Least square means (95%CI) for contact pigs in the vaccinated contact group (blue, solid line) and
unvaccinated contact group (red, solid line) over the two consecutive trials. Pigs with no serological response (NSR) (green, dashed line) are included in the graphical output
but due to low sample size confidence intervals were not available from the GLMM. Asterisks indicate statistically significant differences (Fisher’s exact test, p < 0.05) between
contact pigs in the vaccinated and unvaccinated contact groups on a given day post contact (dpc) Least square means were generated from the binary GLMM (see methods;
Supplementary Appendix A). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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differences in the proportion of contact pigs GTLOD between those
in the vaccinated and unvaccinated contact group was observed for
both nasal shedding (Fig. 4a) and viraemia (Fig. 4b).
3.4. Virus load
AUC for shedder and contact pigs in the vaccinated, unvacci-
nated and NSR (Trial 1 only) group for nasal shedding and viraemia
is shown in Fig. 5. Although NSRs were not included in the statis-
tical analysis, the AUC for NSRs were generally more similar to the
contact pigs in the unvaccinated group. The AUC of contact pigs in
the unvaccinated group was significantly higher than contact pigs
in the vaccinated group (nasal shedding, p < 0.001; viraemia,
p < 0.001) (Supplementary Table A2). There was a significant differ-
ence in the AUC between Trials (Trial 2 > Trial 1, p = 0.0013) for
nasal shedding, but not viraemia (Supplementary Table A2).
3.5. Impact of vaccination and vaccine responsiveness on transmission
dynamics
The mode of the posterior distribution for the parameter a in
Eq. (3) is close to a = 1 (Fig. 6), which strongly suggests that NSRsclosely resemble unvaccinated individuals in their contributions to
the PRRSV transmission dynamics. In fact, 97% of posterior samples
are closer to a = 1 than a = 0 and the Bayes factor between the mod-
els corresponding to a = 1 and a = 0 (calculated by the ratio of the
posterior probability at either value of a) exceeds 100, implying
decisive evidence in support of the first model [33]. Hence NSRs
were considered as unvaccinated pigs in the subsequent model
parameter estimations.
Fig. 7 shows the posterior probability distributions for the var-
ious model parameters from the compartmental model in Fig. 2a
(means and 95% credible intervals for the model parameters are
shown in Table 1). Due to the large overlap in the posterior distri-
butions for the transmission parameter b associated with vacci-
nated and unvaccinated individuals (Fig. 7a), it was not possible
to establish whether vaccination with Flanders08att reduced
PRRSV transmission or not. However, pigs in the vaccinated contact
group were slower to become infectious once exposed (Fig. 7b;
parameter k), had a shorter infectious period (Fig. 7c; parameter
p) and recovered faster (Fig. 7d; parameter c), as shown by the fact
that the posterior distributions are substantially separated (i.e.
there is little overlap in credible intervals). Some unvaccinated pigs
rebound from the L to I state but the data is consistent with no
such rebound for vaccinated pigs (Fig. 7e; parameter j). In fact,
Fig. 5. Viral load. Individual data plot showing area under the curve (AUC) for contact and shedder pigs in the vaccinated (blue) and unvaccinated (red) groups from nasal
shedding (Concentration - Log TCID50.g1) and viraemia (Concentration - Log TCID50.ml1) samples collected throughout the study (n = 52 pigs). Pigs that had no serological
response (NSR) to the vaccination (green) were only present in Trial 1. Black line, representing the median AUC is shown for all groups except the NSR shedders where n = 1.
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 6. Probability distribution for model selection parameter ‘‘a”, where a = 0
implies pigs with no serological response (NSR) behave as thoguh they are
vaccinated and a = 1 implies NSRs behave as though they are unvaccinated.
3056 M. Chase-Topping et al. / Vaccine 38 (2020) 3050–3061there is a Bayes factor of 22 between models without and with this
transition for vaccinated pigs, providing strong evidence that L? I
transitions do not happen under vaccination. On the other hand,
vaccination did not prevent ‘‘recovered” R pigs reverting to the L
state (Fig. 7f; parameter d). Both model parameters (j and d)
occurred at a relatively low rate for both types of individual. Sup-
plementary Table 3 summarises posterior distributions for the
numbers of different types of transition. These reflect the parame-
ter values in Table 1 (in particular, forward transitions
E? I? L? R are significantly more common than reverse transi-
tions R ? L ? I).
A large part of the parameter uncertainty observed in Fig. 7
comes from confounding, which manifests as posterior correla-
tions between different parameters (see Supplementary Appendix
B). For example, confounding between the transmission rates bVac
and bUnvac and incubation rates kVac and kUnvac, arises because of
uncertainty as to whether individuals become infected at a fast
rate and incubate at a slow rate or vice versa. As seen later, this
adversely affects the precision with which R0 estimates can be
Fig. 7. Posterior distributions for the parameter estimates of the epidemiological model. Posterior distributions stratified by group vaccination status for (a) the transmission
rate b, (b) the incubation rate k, i.e. transition rate from exposed to infectious state (c) transition rate from infectious to latent state p, (d) the recovery rate c, (e) the re-
infectious rate j and (f) the re-infected rate d. The blue and red curves represent the results for vaccinated (Vac) and unvaccinated (Unvac) individuals, respectively. Pigs that
had no serological response (NSR) to the vaccination are assumed to behave the same as unvaccinated. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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observed corresponding to uncertainty in the number of L M I
and R M L transition pairs between observed time points.
Fig. 8 shows posterior estimates for the time trends of the num-
ber of individuals in each model compartment for the unvacci-
nated and vaccinated contact groups in both trials. The trials are
presented separately as this may show the effect of the presence
of NSRs on the population; NSRs were only present in the vacci-
nated contact group in Trial 1 (Fig. 8a). The infection process was
slower in the vaccinated contact groups (Fig. 8a&c) as opposed tothe unvaccinated contact groups (Fig. 8b&d). The unvaccinated
contact group was infected earlier, with almost all of the popula-
tion infected by day 5. Recovery was faster in the vaccinated con-
tact group where 50% of the population had recovered by
approximately 18 days as opposed to approximately 25 days in
the unvaccinated contact group (Fig. 8). Despite the small number
of animals used, the dynamic patterns for each compartment seen
in trial 1 (Fig. 8 a&b) are accurately reproduced in trial 2 (Fig. 8c&d)
suggesting that the effect of vaccination is systematic rather than
coming from stochastic variation across trials. In particular, the
Table 1
Posterior parameter estimates for compartmental model. This table shows the mean and 95% credible intervals (CI) for model parameters shown in Fig. 7. Model parameters: the
contact rate b; the incubation rate k; the infectious removal rate p; the recovery rate c; the rate of becoming re-infectious j; and the rate of becoming re-infected d (see Fig. 2a for
reference). Note, pigs that had no serological response (NSR) to the vaccination are treated as unvaccinated.
Description Status Parameter Mean Lower 95% CI Upper 95% CI
Contact rate Vaccinated bVac 0.320 0.0676 0.927
Unvaccinated bUnvac 0.160 0.0729 0.377
Incubation rate Vaccinated kVac 0.131 0.0741 0.217
Unvaccinated kUnvac 0.570 0.323 0.901
Infectious removal rate Vaccinated pVac 0.319 0.192 0.493
Unvaccinated pUnvac 0.138 0.0963 0.188
Recovery rate Vaccinated cVac 0.482 0.289 0.782
Unvaccinated cUnvac 0.118 0.0804 0.165
Rate re-infectious Vaccinated jVac 0.0366 0.000865 0.148
Unvaccinated jUnvac 0.0402 0.0181 0.0721
Rate re-infected Vaccinated dVac 0.0477 0.0150 0.110
Unvaccinated dUnvac 0.0540 0.0223 0.102
Fig. 8. Compartmental populations estimates. Posterior estimates for the time trends for the number of contact pigs in each infection state (compartment of the
epidemiological model). Solid lines show the mean and shaded areas represent 95% credible intervals) for (a) vaccinated contact group in Trial 1 (with pigs that had no
serological response (NSR) to the vaccination considered as unvaccinated), (b) unvaccinated contact group in Trial 1, (c) vaccinated contact group in Trial 2, and (d)
unvaccinated contact group in Trial 2.
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dynamics, although the rate of recovery in the vaccinated contact
group in Trial 1 was approximately 3 days longer than in Trial 2
(Fig. 8a&c).
R0 was calculated for the vaccinated and unvaccinated contact
groups, assuming NSRs as unvaccinated (Fig. 9). As expected, given
that all the pigs in both the unvaccinated and vaccinated contact
groups became infected, our estimate of R0 is large and excludesthe threshold value of R0 = 1 for both groups. The mode or the most
likely estimate of R0 for the vaccinated contact group was approx-
imately 5.0, one half of that observed for the unvaccinated contact
group (mode R0 = 10), although there was considerable overlap in
the posterior distributions of both groups (95% credible intervals:
vaccinated contact group, 2.43–39.7; unvaccinated contact group,
5.93–32.3). This overlap may be partly due to the presence of NSRs
in one of the trials.
Fig. 9. Reproductive ratio R0. The posterior density plots of R0 for the vaccinated
contact group (blue) and the unvaccinated contact group (red). The shaded area is
the 95% credible interval. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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Vaccination is an important weapon in the fight against infec-
tious disease, both in human and livestock populations. Veterinary
vaccines are used in livestock and poultry to improve animal
health, prevent or reduce pathogen transmission, thereby increas-
ing production of livestock in a cost-effective manner [1]. More
efficient animal production and better access to high-quality pro-
tein are essential to feed the growing population. Furthermore,
with the increasing global threats of antimicrobial resistance in
both animals and humans, vaccines are very important tools to
reduce antimicrobial use and thereby slow down the emergence
and spread of antimicrobial resistance. However, it is well estab-
lished that the majority of veterinary vaccines only reduce, not
prevent infection and pathogen shedding [34]. This raises concerns
about the effectiveness of a vaccine to control or eradicate disease
in the field.
It is estimated that veterinary vaccines are available for over
400 diseases affecting mammals, birds and fish including farm ani-
mals, pets and wildlife [35]. Given the enormous scale and implica-
tions of vaccine use in both health and economics, it is clearly
important that their effectiveness be thoroughly evaluated [36].
Most vaccine trials focus on the evaluation of vaccine efficacy or
safety but the impact of vaccination on the spread of infection in
livestock populations is less understood. Only few studies have
evaluated virus transmission using contact models (PRRSV
[5,37,38]; Marek’s Disease [39]; FMD [40]; Avian flu [41]; Swine
flu [42]).
Examining vaccine effectiveness is particularly important for
PRRS due to their failure to reduce PRRS prevalence and their risk
to promote viral evolution to higher virulence. The protocol devel-
oped in this study was a contact model designed to mimic a natural
situation involving the introduction of a highly pathogenic heterol-
ogous strain (only 84% sequence similarity) into a population.
Despite the small sample size in this study, there were clear dif-
ferences in the infection profiles and viral load of the pigs in the
vaccinated and unvaccinated contact groups. Although vaccination
did not prevent infection, it significantly reduced the viral load and
shortened the duration of viraemia and nasal shedding. Nasal
shedding is a key parameter responsible for transmission. Pigs
can be infected by either direct or indirect contact through respira-
tory routes and cause primary infection in the nasal mucosa.
An epidemiological model embedded into a Bayesian inference
framework was used to estimate the effects of vaccination on
underlying transmission parameters from the experimental data.One of the advantages of Bayesian methods is that they can explic-
itly handle uncertainties surrounding assumptions, data and
parameters, making them ideal for analysing small datasets.
Despite a high degree of uncertainty in some parameters (e.g. the
transmission rates b and subsequent R0), the model results reveal
significant beneficial effects of vaccination in some key parameters
affecting PRRSV transmission dynamics within a population, such
as the onset and duration of the infectious period. Similar positive
effects of vaccination have been observed previously [5,43]. Unlike
other studies, however, the credible intervals on R0 estimated in
this study were large for both vaccinated (2.43–39.7) and unvacci-
nated (5.93–32.3) contact pigs with considerable overlap. Vaccina-
tion and PRRSV transmission has been reviewed [4] including
estimates of R0 for similar PRRSV transmission studies. Rose et al.
[5] estimated R0 for unvaccinated pigs as 5.42 (CI95% 2.94–9.04)
and vaccinated pigs as 0.30 (CI95% 0.05–0.96). Pileri et al. [43] esti-
mated R0 for unvaccinated pigs as 2.78 (CI95% 2.13–3.43) and vac-
cinated pigs as 0.53 (CI95% 0.19–0.76). Differences in R0 can be
due to many factors including: the genetic difference between
the vaccination strain and challenge strain (7.3% (ORF5)/ 4.9%
(ORF7) [5] versus 18.7% (ORF5)/ 12% (ORF7), this study); beha-
vioural differences between challenge strains; and the environ-
mental circumstances within a trial (e.g. space per pig,
ventilation, social behaviour) may have an impact on the transmis-
sion. A larger trial involving more contact groups would likely help
to reduce the large credibility intervals observed for other key
parameters, such as the transmission rate b and the transmission
potential R0, and thus to obtain more conclusive estimates for the
impact of vaccination on these pigs.
In contrast to previous vaccination transmission experiments,
this study identified pigs with no serological response (NSR) in
one of the trials comprising 31% (4/13) of the vaccinated animals.
Heterogeneity in vaccine serological response with PRRSV has been
reported in previous studies [20,21] although it is likely underre-
ported as the NSRs are often removed before any analyses are car-
ried out. In one study [21] NSRs represented 12% of all vaccinated
pigs, however, group-level prevalence of NSRs varied from 0% to
40%. Based on viral load and infection profile the NSRs in this study
were more similar to unvaccinated contact pigs. This was con-
firmed by the epidemiological model using objective model selec-
tion methods. Although the conclusion was that the NSRs were
more similar to the unvaccinated contact pigs there was a degree
of uncertainty surrounding this result. This uncertainty may reflect
a direct effect of vaccination, i.e. that vaccination did offer some
level of protection despite the lack of measurable antibody titre
due to cell-mediated immunity. Alternatively, it could reflect indi-
rect benefits provided by the fact that NSRs are in the same
contact-group as vaccinated pigs, which may confer some protec-
tion as a result of lower viral load shedding due to vaccination.
Such beneficial indirect effects of vaccination on non-vaccinated
contact individuals have been reported in other species [37].
Unfortunately, in this study we cannot distinguish between the
two plausible explanations.
In a purely theoretical study Bitsouni et al [3] demonstrate that
even vaccines with no or low levels of sterilizing immunity, or less
than 100% effective coverage, when appropriately applied can pre-
vent, eliminate or largely reduce the prevalence of PRRSV infec-
tions, as long as the vaccine sufficiently speeds up recovery and
reduces pathogen shedding. The results of this study largely con-
firm these model predictions. In particular, the vaccinal strain used
in this study was shown to reduce nasal viral load and thus likely
also host infectivity, as well as the duration of the infectious period
with likely subsequent effects on R0. However, the results of our
study also suggest that incomplete effective vaccine coverage
may have less impact on the transmission dynamics than predicted
by theory, as viral shedding and thus potentially infectivity of non-
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are vaccinated [39]. Such indirect effects of vaccination are cur-
rently not incorporated in typical epidemiological prediction
models.
One of the main reasons for applying vaccines in livestock is to
minimize production loss. In particular, in Europe killed PRRSV vac-
cines are administered to sows to prevent reproduction losses
caused by PRRSV infection [19]. This study did not consider the
impact of vaccination on production traits as the objective was to
examine the impact of vaccination on transmission. In addition, pre-
vious researchusing the samePRRSVchallenge strain as in this study
has shown it to be highly virulent (Supplementary Appendix A).
Hence, one would expect that the observed vaccine-induced reduc-
tions in viral load would also result in reduced production loss.
Similarly, whilst this study provides new important insights
into the impact of vaccines on viral shedding and the transmission
dynamics, their impact on virus evolution still needs to be exam-
ined to get a more complete understanding of how vaccines alter
the pathogen and disease landscape. Such investigations are cur-
rently in progress.5. Conclusion
In the coming decades, new human and animal diseases will
continue to emerge. As a result, veterinary vaccines will continue
to be an important tool to protect human health, animal health,
food safety and food security [44]. This study used a vaccinal strain,
which like most PRRSV vaccines, did not prevent pigs from getting
infected with a heterologous strain and conferred heterogeneous
response to vaccination. However, the vaccinated contact groups
had lower viral load, shorter infectious period and faster recovery
in comparison to the unvaccinated contact groups, thus reducing
the overall transmission potential R0, although probably not
enough to control or eradicate PRRSV in the field. Biosecurity and
other measures (for example closed herds, genetic selection for
PRRS resistance) need to be considered to decrease contact rates
and lower R0 below 1. Future evaluation of veterinary vaccines
would benefit from including transmission experiments coupled
with epidemiological models to more accurately predict vaccine
effectiveness and possibly also vaccine safety in the case of modi-
fied live vaccines with high recombination rates [35] in the field.CRediT authorship contribution statement
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